Some ALK+ NSCLC patients’ cancers may progress beyond the reach of standard treatments such as Tyrosine Kinase Inhibitors or chemotherapy. The question arises as to what potentially useful experimental therapies are in development that may offer hope to these patients. Accordingly, the ALK Positive Clinical Trials Committee has curated some of the most promising treatments that are currently being explored in FDA approved clinical trials that are open to ALK+ patients. The trials described below represent some of the most promising modalities available today for post standard-of-care patients to both explore the newest treatments, and to contribute to other patients that will benefit in the future. Included within each study is the formal clinicaltrials.gov web connection, a layman’s description of the technology involved, the trial contact information, trial location sites, and a description of the company behind the research and therapeutic agent(s). Additional information, advice from other patients, and encouraging community can be found by joining our ALK Positive Patient group at https://www.alkpositive.org/patients2
Phase I Clinical Trial NCT05384626 by Nuvalent, Inc.
Study of NVL-655, ALKOVE-1, a fourth generation Anaplastic Lymphoma Kinase (ALK) Inhibitor in patients with advanced NSCLC and other solid tumors harboring the ALK rearrangement or activating ALK mutation.
Read MoreJune 6, 2022
Phase I Clinical Trial NCT05346494 by Imugene Limited
VAXINIA study of CF33-hNIS, an oncolytic virus, as monotherapy or in combination with Pembrolizumab in adults with metastatic or advanced solid tumors (MAST), including NSCLC
https://clinicaltrials.gov/ct2/show/NCT05346484?term=imugene&draw=2&rank=1
Read MoreTumor Infiltrating Lymphocytes (TIL)
For those ALK+ patients that may be searching for a treatment after TKIs and standard treatments, one interesting option is the clinical trial NCT03645928, the Study of Autologous Tumor Infiltrating Lymphocytes (TIL) in Patients With Solid Tumors, by Iovance Biopharmaceuticals using their product Lifileucel, or LN-145.
Read More
